CD5 Expression in CTCL and Its Implications for Anti-CD5 CAR T-Cell Therapy
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262110411 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Leena Wardeh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA. Hauptthemen laut MEDLINE: CD5 Antigens, Lymphoma, T-Cell, Cutaneous, Immunotherapy, Adoptive, Mycosis Fungoides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cutaneous T-Cell Lymphomas (CTCL) are a heterogenous group of T-cell malignancies in the skin and have poor treatment outcomes in advanced stages. CD5, a surface glycoprotein expressed on most mature T cells, has emerged as a promising target for chimeric antigen receptor (CAR) T-cell therapy in systemic T-cell lymphomas. However, its expression profile in CTCL and relevance for targeted therapy remain unclear. Notably, in CTCL, the cell surface expression of receptors, such as CD7 and CD26, tends to become downregulated on the surfaces of malignant T cells In this study, we analyzed single-cell RNA sequencing (scRNA-seq) data from patients at two institutions with mycosis fungoides (MF), the most common subtype of CTCL with a predominantly CD4 phenotype. We utilized 5 patch/plaque MF skin biopsies (majority from early-stage patients), 8 MF tumor biopsies (all from advanced-stage patients), and 8 healthy control biopsies to evaluate lesion-specific CD5 gene expression on CD4 T cells. We found that CD5 was significantly increased in malignant MF CD4 T cells compared to healthy control CD4 T cells (21.1% of MF CD4 T cells expressed CD5 vs. 5.2% of healthy control CD4 T cells, respectively). In subgroup analysis, patch/plaque stage MF biopsies showed higher expression of CD5 in CD4 T cells than tumor stage MF biopsies. Notably, 94.3% of malignant CD4+ T cells in tumor stage MF lesions exhibited complete CD5 loss compared to only 76.6% in patch-plaque MF lesions, suggesting antigen escape in tumor stage disease. These findings demonstrate that CD5 expression in CTCL is dynamic and varies based on lesion type. Our work suggests CD5 may be a viable therapeutic target in MF with patch/plaque presentations but may not be as effective in advanced stages of MF with tumor presentations. This work informs CD5 gene expression in MF based on clinical lesion type and further information is needed to clarify clinical implications as a future therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
- Department of Dermatology, Emory University, Atlanta, GA 30322, USA.
- Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
- Department of Hematology and Medical Oncology, Emory University, Atlanta, GA 30322, USA.
ORCID-Profile: Leena Wardeh, Madeline Williams, Courtney Prestwood, Zachary Wolner, Neda Nikbakht
Zitieren
APA
Wardeh, L., Williams, M., Prestwood, C., Wolner, Z., & Nikbakht, N. (2025). CD5 Expression in CTCL and Its Implications for Anti-CD5 CAR T-Cell Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110411
Vancouver
Wardeh L, Williams M, Prestwood C, Wolner Z, Nikbakht N. CD5 Expression in CTCL and Its Implications for Anti-CD5 CAR T-Cell Therapy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110411
BibTeX
@article{Wardeh2025,
author = {Wardeh, Leena and Williams, Madeline and Prestwood, Courtney and Wolner, Zachary and Nikbakht, Neda},
title = {CD5 Expression in CTCL and Its Implications for Anti-CD5 CAR T-Cell Therapy},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262110411}
}
EUVIMED